🇺🇸 FDA
Patent

US 10576073

Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound

granted A61KA61K31/4465A61P

Quick answer

US patent 10576073 (Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound) held by Theravance Biopharma R&D IP, LLC expires Mon Feb 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Biopharma R&D IP, LLC
Grant date
Tue Mar 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/4465, A61P, A61P11/06, A61P13/00